AURORA CANNABIS INC (ACB) Stock Fundamental Analysis
USA - NASDAQ:ACB - CA05156X8504 - Common Stock
4.21 USD
+0.13 (+3.19%)
4.2369 USD
+0.03 (+0.64%)
We assign a fundamental rating of 3 out of 10 to ACB. ACB was compared to 192 industry peers in the Pharmaceuticals industry. ACB may be in some trouble as it scores bad on both profitability and health. ACB is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
ACB had a positive operating cash flow in the past year.
ACB had negative earnings in 4 of the past 5 years.
ACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ACB has a Return On Assets of -7.78%. This is in the better half of the industry: ACB outperforms 70.31% of its industry peers.
Looking at the Return On Equity, with a value of -11.07%, ACB is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ACB (1.69%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of ACB has declined.
ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
The number of shares outstanding for ACB has been reduced compared to 5 years ago.
The debt/assets ratio for ACB has been reduced compared to a year ago.
2.2 Solvency
ACB has an Altman-Z score of -10.54. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.54, ACB is doing worse than 70.83% of the companies in the same industry.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.07, ACB perfoms like the industry average, outperforming 52.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.54 |
ROIC/WACCN/A
WACC8.15%
2.3 Liquidity
ACB has a Current Ratio of 3.41. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.41, ACB is in line with its industry, outperforming 55.21% of the companies in the same industry.
A Quick Ratio of 1.63 indicates that ACB should not have too much problems paying its short term obligations.
The Quick ratio of ACB (1.63) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 99.67% over the past year.
Looking at the last year, ACB shows a very strong growth in Revenue. The Revenue has grown by 23.87%.
Measured over the past years, ACB shows a small growth in Revenue. The Revenue has been growing by 6.94% on average per year.
EPS 1Y (TTM)99.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%157.81%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%14.31%
3.2 Future
The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.92% on average over the next years.
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.87%
Revenue Next 5Y7.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Forward Earnings ratio of 12.61 indicates a correct valuation of ACB.
84.38% of the companies in the same industry are more expensive than ACB, based on the Price/Forward Earnings ratio.
ACB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACB's earnings are expected to grow with 81.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y206.48%
EPS Next 3Y81.3%
5. Dividend
5.1 Amount
No dividends for ACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.21
+0.13 (+3.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.09%
Inst Owner Change54.99%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap236.81M
Revenue(TTM)367.13M
Net Income(TTM)-58.89M
Analysts73.33
Price Target5.76 (36.82%)
Short Float %12.24%
Short Ratio4.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.2%
Min EPS beat(2)-216.23%
Max EPS beat(2)169.83%
EPS beat(4)2
Avg EPS beat(4)1005.23%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)458.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)5.14%
Revenue beat(4)3
Avg Revenue beat(4)4.75%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)13.79%
Revenue beat(8)6
Avg Revenue beat(8)4.5%
Revenue beat(12)8
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-0.66%
PT rev (3m)-10.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.61 | ||
| P/S | 0.91 | ||
| P/FCF | N/A | ||
| P/OCF | 148.49 | ||
| P/B | 0.63 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.33
Fwd EY7.93%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)0.03
OCFY0.67%
SpS4.64
BVpS6.72
TBVpS5.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.78% | ||
| ROE | -11.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.69% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.37% | ||
| Cap/Sales | 5.6% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.41 | ||
| Quick Ratio | 1.63 | ||
| Altman-Z | -10.54 |
F-Score5
WACC8.15%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%157.81%
EPS Next Y-288.53%
EPS Next 2Y206.48%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)23.87%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%14.31%
Revenue Next Year8.72%
Revenue Next 2Y7.21%
Revenue Next 3Y6.87%
Revenue Next 5Y7.92%
EBIT growth 1Y-6.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.45%
EBIT Next 3Y30.77%
EBIT Next 5Y25.8%
FCF growth 1Y87.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.77%
OCF growth 3YN/A
OCF growth 5YN/A
AURORA CANNABIS INC / ACB FAQ
Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ACB.
Can you provide the valuation status for AURORA CANNABIS INC?
ChartMill assigns a valuation rating of 3 / 10 to AURORA CANNABIS INC (ACB). This can be considered as Overvalued.
What is the profitability of ACB stock?
AURORA CANNABIS INC (ACB) has a profitability rating of 2 / 10.